Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2006 1
2007 3
2008 5
2009 4
2010 9
2011 14
2012 13
2013 11
2014 11
2015 10
2016 3
2017 4
2018 5
2019 2
2020 1
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25429159

85 results

Results by year

Filters applied: . Clear all
Page 1
Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma.
Carr R, Fanti S, Paez D, Cerci J, Györke T, Redondo F, Morris TP, Meneghetti C, Auewarakul C, Nair R, Gorospe C, Chung JK, Kuzu I, Celli M, Gujral S, Padua RA, Dondi M; IAEA Lymphoma Study Group. Carr R, et al. J Nucl Med. 2014 Dec;55(12):1936-44. doi: 10.2967/jnumed.114.145326. J Nucl Med. 2014. PMID: 25429159 Free article.
Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
Cerci JJ, Györke T, Fanti S, Paez D, Meneghetti JC, Redondo F, Celli M, Auewarakul C, Rangarajan V, Gujral S, Gorospe C, Campo MV, Chung JK, Morris TP, Dondi M, Carr R; IAEA Lymphoma Study Group. Cerci JJ, et al. J Nucl Med. 2014 Oct;55(10):1591-7. doi: 10.2967/jnumed.113.134486. Epub 2014 Sep 11. J Nucl Med. 2014. PMID: 25214642 Free article.
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Pardal E, et al. Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28. Br J Haematol. 2014. PMID: 25066542 Free article. Clinical Trial.
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Halasz LM, et al. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18. Int J Radiat Oncol Biol Phys. 2012. PMID: 22607911
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea). González-Barca E, et al. Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695. Nucl Med Commun. 2013. PMID: 23880897 Clinical Trial.
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Lancet Oncol. 2008 May;9(5):435-44. doi: 10.1016/S1470-2045(08)70078-0. Epub 2008 Apr 8. Lancet Oncol. 2008. PMID: 18400558 Clinical Trial.
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH. Schöder H, et al. J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30. J Nucl Med. 2016. PMID: 26719374 Free PMC article. Clinical Trial.
85 results